Emerging Research

Survodutide

GLP & Metabolic · ['BI 456906', 'GLP-1/GCGR dual agonist']

Survodutide (BI 456906) is an investigational GLP-1 receptor and glucagon receptor dual agonist peptide studied in clinical trials for metabolic and liver-related endpoints.

🔬 Research use only — not for human or veterinary use. K4 Elite does not provide dosing instructions.

Molecular Formula

C192H289N47O61

Molecular Weight

4232 g/mol

PubChem

CID 168429725 ↗

Research Level

Emerging Research

Browse the store →

Survodutide (development code BI 456906) is an investigational peptide characterized in the literature as a dual agonist of the glucagon-like peptide-1 (GLP-1) receptor and the glucagon (GCG) receptor. It has been studied in a program of clinical trials examining metabolic endpoints and liver-associated outcomes [1][2].

The compound belongs to the broader class of multi-receptor metabolic peptides that combine incretin and glucagon signaling in a single molecule. It carries an acylated (fatty-acid) modification associated with an extended pharmacokinetic profile in the published descriptions [1].

As an investigational agent, survodutide has not received general marketing authorization at the time of writing and is described in research contexts only.

Survodutide is reported to activate both the GLP-1 receptor and the glucagon receptor. In the published literature, GLP-1 receptor activity is linked to glucose-dependent insulin secretion and appetite-related pathways, while glucagon receptor activity is linked to hepatic metabolism and energy-expenditure pathways [1][3].

The dual mechanism has been studied specifically in the context of metabolic-associated steatotic liver disease (MASLD/NASH) research and body-weight endpoints. All effects described here are attributed to cited studies.

Dual GLP-1R/GCGR receptor pharmacology and selectivity profiling [1]
Metabolic dysfunction-associated steatohepatitis (MASH/NASH) endpoints in a phase 2 trial [2]
Body-weight change in adults with overweight or obesity in randomized trials [3]
Glycemic and metabolic parameters in participants with type 2 diabetes [1]
Hepatic fat fraction and liver-associated biomarkers in imaging-based studies [2]

📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.

Phase 2 MASH trial: A randomized, double-blind, placebo-controlled phase 2 study evaluated survodutide in adult participants with biopsy-confirmed metabolic dysfunction-associated steatohepatitis, reporting histological improvement endpoints across dose groups versus placebo [2]. Presented for scientific reference only.

Phase 2 weight-management trial: A randomized controlled trial in adults with overweight or obesity measured percentage change in body weight across escalating dose groups over the treatment period, reporting dose-related outcomes versus placebo [3].

Preclinical and phase 1 characterization: In vitro receptor studies and early-phase human pharmacokinetic studies characterized dual-agonist potency and the acylated peptide's exposure profile [1].

Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.

GLP-1 receptor agonists (e.g., liraglutide)Caution

Overlapping GLP-1 receptor pharmacology relevant to comparative research.

Tirzepatide / other dual or triple agonistsCaution

Shared multi-receptor targets studied within the same class.

Insulin and secretagoguesCaution

Glycemic pathways studied together in metabolic trials.

MazdutideCompatible

Structurally comparable GLP-1R/GCGR dual agonist studied in parallel literature.

What is survodutide?

An investigational dual GLP-1 receptor / glucagon receptor agonist peptide (BI 456906) studied in clinical trials [1].

What conditions have been studied in trials?

Published trials report metabolic dysfunction-associated steatohepatitis (MASH) endpoints and body-weight endpoints in adults [2][3].

Is survodutide approved?

It is described as investigational and has not received general marketing authorization at the time of writing [2].

How does its mechanism differ from a single GLP-1 agonist?

It adds glucagon receptor agonism to GLP-1 activity, a combination studied for hepatic and metabolic endpoints [1][3].

Can I use this product personally?

No. It is supplied for laboratory research use only and is not intended for human or veterinary use, nor to diagnose, treat, cure, or prevent any disease.

Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.